Diabetic dyslipidaemia: Effective management reduces cardiovascular risk

Atherosclerosis Supplements

Volumn 6, Issue 2, 2005, Pages 37-43

  Leiter, Lawrence A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Diabetes; Dyslipidaemia; Macrovascular complications; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANAMNESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; DYSLIPIDEMIA; FATALITY; HEALTH PROGRAM; HEALTH SURVEY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; MEDICAL SPECIALIST; MORTALITY; OUTCOMES RESEARCH; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; VASCULAR DISEASE;

EID: 17044362675     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2005.02.007     Document Type: Article

References (55)

1. B. Balkau, M. Pyorala, and M. Shipley Non-cardiovascular disease mortality and diabetes mellitus Lancet 350 1997 1680
2. W.A. Hsueh, and R.E. Law Diabetes is a vascular disease J Investig Med 46 1998 387 390
3. Department of Health. The National Service Framework for diabetes; 2002. www.doh.gov.uk/nsf/diabetes.
4. A. Fagot-Campagna, T.L. Gary, and S.M. Benjamin Cardiovascular risk in diabetes: a story of missed opportunities Diabetes Care 24 2001 2015 2016
5. M.F. Sacks, A.M. Tomkin, and J. Shepherd Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
6. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
7. R. Collins Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
8. CARE Investigators Cardiovascular event and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) trial Circulation 98 1998 2513 2519
9. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
10. R.C. Turner, H. Millns, and H.A. Neil Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 1998 823 828
11. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
12. S.M. Haffner, R.A. Valdez, and H.P. Hazuda Prospective analysis of the insulin resistance syndrome (syndrome X) Diabetes 41 1992 715 722
13. PAIR Advisory Panel The insulin resistance syndrome and coronary artery disease Coron Artery Dis 14 2003 335 348
14. K.R. Feingold, C. Grunfeld, M. Pang, W. Doerrler, and R.M. Krauss LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes Arterioscler Thromb 12 1992 1496 1502
15. E. Barrett-Connor, S.M. Grundy, and M.J. Holdbrook Plasma lipids and diabetes mellitus in an adult community Am J Epidemiol 115 1982 657 663
16. D.J. Betteridge Diabetic dyslipidaemia Eur J Clin Invest 29 Suppl. 2 1999 12 16
17. A. Chait, and E.L. Bierman 13th ed. C.R. Kahn G.C. Weir Joslin's diabetes mellitus 1994 Lea & Febiger Philadelphia p. 648-64
18. S.M. Haffner Management of dyslipidemia in adults with diabetes Diabetes Care 21 1998 160 178
19. K. Pyorala, T.R. Pedersen, and J. Kjekshus Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
20. G. Paolisso, and B.V. Howard Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus Diabet Med 15 1998 360 366
21. S.M. Haffner, R. D'Agostino Jr., and L. Mykkanen Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study Diabetes Care 22 1999 562 568
22. American Diabetes Association Management of Dyslipidemia in Adults With Diabetes. Position statement Diabetes Care 26 Suppl. 1 2003 S83 S86
23. W.B. Kannel, and D.L. McGee Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study Diabetes Care 2 1979 120 126
24. J.R. Kaseta, D.F. Skafar, J.L. Ram, S.J. Jacober, and J.R. Sowers Cardiovascular disease in the diabetic woman J Clin Endocrinol Metab 84 1999 1835 1838
25. L. Niskanen, A. Turpeinen, I. Penttila, and M.I. Uusitupa Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis Diabetes Care 21 1998 1861 1869
26. K. Gu, C.C. Cowie, and M.I. Harris Diabetes and decline in heart disease mortality in US adults JAMA 281 1999 1291 1297
27. L. Mosca AHA Evidence-based guidelines for cardiovascular disease prevention in women Arterioscler Thromb Vasc Biol 24 2004 e29 e50
28. S. Vijan American College of Physicians Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians Ann Intern Med 140 2004 650 658
29. H.M. Colhoun, M.J. Thomason, and M.I. Mackness Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes Diabet Med 19 2002 201 211
30. H.M. Colhoun The Collaborative Atorvastatin Diabetes Study (CARDS) Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
31. B.J. Hoogwerf, A. Waness, and M. Cressman Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial Diabetes 48 1999 1289 1294
32. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
33. C.P. Cannon, E. Braunwald, and C.H. McCabe Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
34. S.J. Robins, D. Collins, and J.T. Wittes Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
35. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
36. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
37. G. Schectman, and J. Hiatt Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment Ann Intern Med 125 1996 990 1000
38. R.S. Safeer, and C.L. Lacivita Choosing drug therapy for patients with hyperlipidemia Am Fam Phys 61 2000 3371 3382
39. C. Gagne Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia Circulation 105 2002 2469 2475
40. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
41. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
42. Morse JS, Brown BG, Zhao XQ. Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose. American College of Cardiology 50th Scientific Session; 2001. p. 842-9 [Abstract].
43. X.Q. Zhao, J.S. Morse, and A.A. Dowdy Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) Am J Cardiol 93 2004 307 312
44. Action to Control Cardiovascular Risk in Diabetes (ACCORD). Available at: www.accordtrial.org/public/index.cfm.
45. Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
46. American Diabetes Association Standards of medical care in diabetes Diabetes Care 27 Suppl. 1 2004 S15 S35
47. American Diabetes Association Dyslipidemia management in adults with diabetes Diabetes Care 27 Suppl. 1 2004 S68 S71
48. Leiter LA, Betteridge DJ. The AUDIT Study: a worldwide survey of physician attitudes about diabetic dyslipidemia. In: Proceedings of the 64th Annual Scientific Sessions of the American Diabetes Association 2004. [Abstract 1170-P] Available at: www.diabetes.org.
49. P.B. George, K.J. Tobin, R.A. Corpus, W.H. Devlin, and W.W. O'Neill Treatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines Am Heart J 142 2001 857 863
50. T.A. Pearson, I. Laurora, H. Chu, and S. Kafonek The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
51. S.H. Saydah, J. Fradkin, and C.C. Cowie Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 291 2004 335 342
52. The ANDROMEDA Study Investigators Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. 74th European Atherosclerosis Society Congress Atherosclerosis 5 Suppl. 1 2004 107 108 [Abstract M464]
53. The URANUS Study Investigators Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: results of the URANUS study. 74th European Atherosclerosis Society Congress 2004 Atherosclerosis 5 Suppl. 1 2004 107 [Abstract M463]
54. The Dutch CORALL Study Group Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes. 74th European Atherosclerosis Society Congress 2004 Atherosclerosis 5 Suppl. 1 2004 118 [Abstract M513]
55. T.R. Pedersen, O. Faergeman, and J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study Am J Cardiol 94 2004 720 724